ABBV-324 for advanced liver or lung cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have either advanced liver cancer (HCC) that has spread or can't be removed, or advanced squamous lung cancer (LUSC) that has spread
- You are able to be up and about (ECOG 0 or 1) – meaning you can do light work or are fully active
- If you have liver cancer, your liver function must be well preserved (Child-Pugh A) and you must have had at least one prior systemic cancer treatment
- You must not have had lenvatinib (for liver cancer) or have serious lung problems like interstitial lung disease
- Any prior cancer treatment must have been stopped at least 14 days before starting this study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
This trial tests a new drug (WGI-0301) combined with an existing liver cancer medicine (lenvatinib). It aims to see if the combination can help people with advanced liver cancer when other treatments haven't worked.
This study tests a new treatment (BGB-B2033) for advanced liver cancer that has returned or not responded to previous immune therapy. It compares this new drug to the standard options sorafenib or lenvatinib, which are targeted pills. The goal is to see if BGB-B2033 can help shrink or slow the cancer better than the current treatments.
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial tests whether adding a targeted procedure (ablation) to burn away cancer spots, when combined with lenvatinib and an immunotherapy drug (PD-1 inhibitor), can help control liver cancer that has spread to a few places. It's for people whose liver tumors are already responding to treatment.
Hear when a new Hepatocellular Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.